DAR-0100a

Overview: 

Selective Dopamine Receptor D1 agonist for cognitive improvement (Parkinson's Disease, schizophrenia)

Status: 

Purdue Faculty: 

Dr. David Nichols Professor Emeritus

Clinical Trial Information: 

Phase 2 Trial - A D1 Agonist For Working Memory

Phase 2 Trial - Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder (SPD)

Phase 1 Trial - Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders

Phase 1 Trial - Infusion Laboratory: Protocol 4 (Dihydrexidine)

Development Partner: 

Research Articles: 

A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia

Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder

A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia

A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia

Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] raclopride

Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents

Dihydrexidine--the first full dopamine D1 receptor agonist

Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist